Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond.When phosphodiesterase is mentioned, it usually refers to cyclic nucleotide phosphodiesterases, which are discussed below and have significant clinical implications. There are numerous other families of phosphodiesterases, however, including the phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, in addition to a large number of less well-studied small-molecule phosphodiesterases.A group of enzymes known as cyclic nucleotide phosphodiesterases breaks down the phosphodiester bond in the second messenger molecules cAMP and cGMP. Within subcellular domains, they control the cyclic nucleotide signaling's amplitude, duration, and localization. Therefore, PDEs play a crucial role in controlling the signal transduction process that these second messenger molecules mediate.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V87666 | Denbufylline | 57076-71-8 | Denbufylline (BRL 30892) is a phosphodiesterase-4 (PDE4) inhibitor. |
|
V103052 | Desethyl sildenafil | 139755-91-2 | Desethylsildenafil (Sildenafil Impurity C) is an impurity of sildenafil. |
|
V79157 | Dipyridamole-d16 (Dipyridamole-d16) | Dipyridamole-d16 is the deuterated form of Dipyridamole. | |
|
V72033 | Dipyridamole-d20 (Dipyridamole d20) | 1189983-52-5 | Dipyridamole-d20 is the deuterated form of Dipyridamole. |
|
V72083 | Doxofylline-d4 (doxofylline d4) | 1346599-13-0 | Doxofylline-d4 is the deuterium labelled form of Doxofylline. |
|
V72032 | Doxofylline-d6 (doxofylline d6) | 1219805-99-8 | Doxofylline-d6 is the deuterium labelled form of Doxofylline. |
|
V2193 | DSR-141562 | 2007975-22-4 | DSR-141562 is a novel, potent, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. |
|
V87674 | DTA | 654-62-6 | DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase. |
|
V4471 | Edelinontrine (PF-04447943) | 1082744-20-4 | PF-04447943 (PF04447943) is a novel and potent inhibitor of human recombinantPDE9A with the potential for the treatment of cognitive disorders. |
|
V83236 | EHNA HCl | 51350-19-7 | EHNA HCl is a PDE2 inhibitor |
|
V30046 | EHNA hydrochloride | 58337-38-5 | EHNA HCl, the hydrochloride salt of EHNA, is a novel and potent inhibitor of adenosine deaminase, also an inhibitor of cGMP-stimulated phosphodiesterase (PDE2) with IC50 of 0.8 - 4 μM. |
|
V89636 | EMD 53998 | 120223-04-3 | EMD 53998 is a cardiac inotropic agent that acts as a phosphodiesterase III (PDE III) inhibitor and calcium sensitizer to enhance myocardial contractility. |
|
V87665 | endo CNTinh-03 | 345288-49-5 | Endo CNTinh-03 inhibits the increase in cAMP and cGMP induced by agonists of G protein-coupled receptors, adenylate cyclase, and guanylate cyclase (IC50 of 4 μM). |
|
V72019 | Enpp-1-IN-12 | 2631703-41-6 | Enpp-1-IN-12 (Compound 43) is a potent and orally bioactive ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor (antagonist) with Ki of 41 nM. |
|
V72070 | Enpp-1-IN-15 | 2756218-99-0 | Enpp-1-IN-15 (Compound 88a) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp-1) inhibitor (antagonist) with Ki of 0.00586 nM. |
|
V72023 | Enpp-1-IN-16 | 2289739-47-3 | Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. |
|
V72096 | Enpp-1-IN-17 | 2289736-54-3 | Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor (antagonist) with inhibition constants (Kis) of cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. |
|
V72074 | Enpp-1-IN-19 | 2738583-25-8 | Enpp-1-IN-19 (compound 29f) is an orally bioavailable ENPP1 inhibitor that can suppress cGAMP hydrolysis by ENPP1 (IC50=68 nM). |
|
V87003 | Enpp-1-IN-20 | Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor with an IC50 of 0.09 nM. | |
|
V103606 | Enpp-1-IN-21 | 2803505-78-2 | Enpp-1-IN-21 (compound 4g) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor with IC50 of 0.45 and 0.19 μM for ENPP1 and ENPP3, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
